dc.contributor.author | Mirzaei, Sepideh | |
dc.contributor.author | Gholami, Mohammad Hossein | |
dc.contributor.author | Hashemi, Farid | |
dc.contributor.author | Zabolian, Amirhossein | |
dc.contributor.author | Vasheghani Farahani, Mahdi | |
dc.contributor.author | Hushmandi, Kiavash | |
dc.contributor.author | Zarrabi, Ali | |
dc.contributor.author | Goldman, Aaron | |
dc.contributor.author | Ashrafizadeh, Milad | |
dc.contributor.author | Orive Arroyo, Gorka | |
dc.date.accessioned | 2022-02-10T13:15:02Z | |
dc.date.available | 2022-02-10T13:15:02Z | |
dc.date.issued | 2022-02 | |
dc.identifier.citation | Drug discovery today 27(2) : 436-455 (2022) | es_ES |
dc.identifier.issn | 1878-5832 | |
dc.identifier.uri | http://hdl.handle.net/10810/55419 | |
dc.description.abstract | P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX) resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2, HIF-1alpha, miRNAs, and long noncoding (lnc)RNAs, to reveal their participation in DOX resistance. These antitumor compounds and genetic tools synergistically reduce P-gp expression. Furthermore, ATP depletion impairs P-gp activity to enhance the antitumor activity of DOX. Nanoarchitectures, including liposomes, micelles, polymeric nanoparticles (NPs), and solid lipid nanocarriers, have been developed for the co-delivery of DOX with anticancer compounds and genes enhancing DOX cytotoxicity. Surface modification of nanocarriers, for instance with hyaluronic acid (HA), can promote selectivity toward cancer cells. We discuss these aspects with a focus on P-gp expression and activity. | es_ES |
dc.description.sponsorship | GO wish to thank the Spanish Ministry of Economy, Industry,
and Competitiveness (PID2019-106094RB-I00/AEI/10.13039/50
1100011033) and technical assistance from the ICTS NANBIOSIS
(Drug Formulation Unit, U10) at the University of the Basque
Country. We also appreciate the support from the Basque Coun-
try Government (Grupos Consolidados, No ref: IT907-16). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/PID2019-106094RB-I00 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.title | Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S1359644621004281?via%3Dihub#! | es_ES |
dc.identifier.doi | 10.1016/j.drudis.2021.09.020 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | es_ES |
dc.departamentoeu | Farmazia eta elikagaien zientziak | es_ES |